Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative window-of-opportunity study of Debio 1143 with or without cisplatin in resectable head and neck squamous cell carcinoma
2014-004655-31Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of xevinapant in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Debiopharm. Primary endpoint: Change in tumor cIAP-1 levels. Started Apr 2015; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2014-004655-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004655-31.